{"idx":"f27298ed-15be-4fba-b1f8-f10b2f3f6592","name":"Project 3","children":[{"idx":"2931ab66-e591-45f6-a6f1-32f5e333c509","name":"Scientific Protocol","custparents":[{"idx":"edd76f6a-da61-4d5b-939a-6f6cb3f079db"},{"idx":"f27298ed-15be-4fba-b1f8-f10b2f3f6592"}],"children":[{"idx":"fe0339d3-cb8e-4cd5-8a62-7e3fc7e551c0","name":"substeps","custparents":[{"idx":"MY985829e8-14f7-4a67-86ac-167da3d62fa4"},{"idx":"2931ab66-e591-45f6-a6f1-32f5e333c509"}],"children":[{"idx":"e2c25340-f1bc-4c39-8441-8de70d6d1d05","name":"Introduction","custparents":[{"idx":"fe0339d3-cb8e-4cd5-8a62-7e3fc7e551c0"}],"children":[],"_substeps":{"idx":"MY02552ac5-2736-4403-bb66-c89f5fd64c5e","name":"substeps","custparents":[{"idx":"MY02eba6c8-164c-401d-bbc6-0295a3e73cd5"}],"children":[{"idx":"MY1ab790b4-79cd-445f-8c16-6007966bb38f","name":"physician characteristics impact adh","custparents":[{"idx":"MY02552ac5-2736-4403-bb66-c89f5fd64c5e"}],"children":[{"idx":"MY156e3eff-8cca-4417-9edf-4c785aecf367","name":"Physician impact fit into the framework","custparents":[{"idx":"MY1ab790b4-79cd-445f-8c16-6007966bb38f"},{"idx":"MY1ab790b4-79cd-445f-8c16-6007966bb38f"}],"NodeDescription":"<p>///t</p><p>According to a well-accepted world health organization (WHO) framework,<sup>(1)</sup> determinants of non-adherence can be classified into five categories: patient-related; socio-economic environmental; disease-related; treatment-related; and healthcare provider/system-related.<sup>(1)</sup> Physicians can affect determinants in all five of these categories, given their broad responsibilities pertaining to diagnosis, education, prescribing, and follow-up. Indeed, preliminary studies have linked physician roles to medication adherence through activities such as counseling/ education,<sup>(2-6)</sup> follow up after prescribing a new medication, <sup>(7-10)</sup> and choice of prescriptions. <sup>(11-13)</sup></p><p>t///</p>"},{"idx":"MY8f981243-fde9-4c5b-a979-1703f8608d0d","name":"physician impact through trust and communication","custparents":[{"idx":"MY1ab790b4-79cd-445f-8c16-6007966bb38f"}],"NodeDescription":"<p>///t</p><p>It is highly possible that many of the activities associated with medication adherence may simply be indicators of effective relationships rather than independent, causal factors. If so, the strength of the patient physician relationship may be a more important factor than the number of follow-up visits or the time spent on educational activities. Evidence supporting the importance of a strong physician-patient relationship is clear: patient reported trust and communication are consistently associated with high adherence.<sup>(1, 14-19)</sup></p><p>t///</p>"}]},{"idx":"MYa094ea87-7ef9-4ddd-b87d-c0d682fd8a62","name":"Concordance to adherence","custparents":[{"idx":"MY02552ac5-2736-4403-bb66-c89f5fd64c5e"}],"NodeDescription":"<p>///t</p><p>The literature <a href=\"#_msocom_1\" target=\"_blank\">[BD1]</a>suggests that a trustful relationship between physicians and patients can be influenced where these individuals had concordance/disconcordance on certain characteristics, i.e., whether or not share similar demographic or racial characteristics<a href=\"#_msocom_2\" target=\"_blank\">[LL2]</a>. For example, African-Americans patients under care of white physicians (i.e., disconcordance on ethnicity) was associated with suboptimal medication adherence.<sup>(20)</sup> On the contrary, white patients under care of white physicians (i.e., racial concordance) was associated with improved medication adherence.<sup>(21)</sup>Concordance can be based on characteristics other than race, such as age, or sex. Although patient age and sex have been tested frequently in adherence studies <a href=\"#_msocom_3\" target=\"_blank\">[EC3]</a>in the past with inconsistent results,<sup>(22)</sup> it is possible that the impact of age and sex may depend on concordance between patients and their physicians’<a href=\"#_msocom_4\" target=\"_blank\">[LL4]</a> demographic characteristics. To date, such associations have not been fully explored. Findings of studies examining physician-patient concordance (i.e., physicians and his/her patients share the same characteristics such as age, sex, or ethnicity) <a href=\"#_msocom_5\" target=\"_blank\">[LL5]</a>may be relevant to the impact of relationships with medication adherence.</p><p><a href=\"#_msoanchor_1\" target=\"_blank\">[BD1]</a>COME BACK TO THIS!!</p><p><a href=\"#_msoanchor_2\" target=\"_blank\">[LL2]</a>Here again, explain what you mean by discordance. </p><p><span style=\"background-color: yellow;\">[SY] Added</span></p><p><a href=\"#_msoanchor_3\" target=\"_blank\">[EC3]</a>Do you mean the impact of the age and sex of the patient? If so, maybe explicitly state that.</p><p><span style=\"background-color: yellow;\">[SY] Changed</span></p><p><a href=\"#_msoanchor_4\" target=\"_blank\">[LL4]</a>Why limit this statement to GP? In the paragraph above, you do not focus specifically on GPs </p><p><span style=\"background-color: yellow;\">[SY] Changed</span></p><p><a href=\"#_msoanchor_5\" target=\"_blank\">[LL5]</a>I would recommend that you add an explanation here about what you mean by concordance. </p><p><span style=\"background-color: yellow;\">[SY] Added</span></p><p>t///</p>"},{"idx":"MY37f76870-7957-47a7-9954-bb2e12c35949","name":"Aim of the study","custparents":[{"idx":"MY02552ac5-2736-4403-bb66-c89f5fd64c5e"}],"NodeDescription":"<p>///t</p><p>The aim of this study <a href=\"#_msocom_1\" target=\"_blank\">[BD1]</a>was to examine the impact of patient-physician concordance of age or <a href=\"#_msocom_2\" target=\"_blank\">[BD2]</a>sex on the probability of medication adherence. <a href=\"#_msoanchor_1\" target=\"_blank\">[BD1]</a>We may consider adding a couple of sentences outlining how concordance could impact adherence at not only the individual level but could also partially explain the occurrence of high performing physicians who have higher than avg rates of opt adherence ….. not sure if this is necessary but perhaps it wouldassesst the reader in understanding the obectives?</p><p><a href=\"#_msoanchor_2\" target=\"_blank\">[BD2]</a>Should this be “or” instead of “and”</p><p><span style=\"background-color: yellow;\">[SY] Changed</span></p><p>t///</p>"}]}},{"idx":"1dc84ccb-771b-44fe-9a4d-7304df402046","name":"Methods","custparents":[{"idx":"fe0339d3-cb8e-4cd5-8a62-7e3fc7e551c0"},{"idx":"fe0339d3-cb8e-4cd5-8a62-7e3fc7e551c0"}],"children":[{"idx":"210a42cb-6db1-4b37-9796-16d79dc503c1","name":"substeps","custparents":[{"idx":"1dc84ccb-771b-44fe-9a4d-7304df402046"}],"children":[{"idx":"48eb234c-14e3-44fb-a544-0a639d7918ce","name":"Hypotheses and Study Objectives","custparents":[{"idx":"210a42cb-6db1-4b37-9796-16d79dc503c1"}],"children":[{"idx":"d1893bba-8184-4ed7-9860-b4bc68ddaa92","name":"Obj1 to describe","custparents":[{"idx":"48eb234c-14e3-44fb-a544-0a639d7918ce"},{"idx":"48eb234c-14e3-44fb-a544-0a639d7918ce"}],"NodeDescription":"<p>///t</p><p><u>Objective 1: </u><a href=\"#_msocom_1\" target=\"_blank\">[BD1]</a> To d<u>escribe and rank phyisicians based on the prevalence of optimal adherence witin their patient panel.</u></p><p><a href=\"#_msoanchor_1\" target=\"_blank\">[BD1]</a>Do you think it would help make this more clear if we had the first objective that was simply to “Describe and rank phyisicians based on the prevalence of optimal adherence witin their “patient pool”(I wish we could come up with a better term other than “pool”.Let’s keep thinking about possible terms that might be better. </p><p>t///</p><p><br></p>"},{"idx":"e30a9ff7-369e-4d57-aa8e-cb0dec291bd5","name":"Obj2 %concord to % adh doc level","custparents":[{"idx":"48eb234c-14e3-44fb-a544-0a639d7918ce"},{"idx":"48eb234c-14e3-44fb-a544-0a639d7918ce"}],"NodeDescription":"<p>///t</p><p><br></p><p><u>Objective 2: To determine if a high proportion of age and/or sex concordant patients in a prescriber’s patient pool </u><a href=\"#_msocom_1\" target=\"_blank\">[LL1]</a><u>is associated with an increased prevalence of optimal </u><a href=\"#_msocom_2\" target=\"_blank\">[BD2]</a><u>adherence.</u></p><p>Hypothesis: A high proportion of age and /or sex concordance within a prescribers’ patient pool (?) patients is associated with an increased prevalence of optimal medication adherence<a href=\"#_msocom_3\" target=\"_blank\">[BD3]</a>.</p><p><a href=\"#_msoanchor_1\" target=\"_blank\">[LL1]</a>You have one hypothesis but two objectives. I do not see a good fit between the objectives and the hypothesis. Why do you not mention the prescriber in your hypothesis?</p><p><span style=\"background-color: yellow;\">[SY] Changed</span></p><p><a href=\"#_msoanchor_2\" target=\"_blank\">[BD2]</a>To determine if the prevalenceof optimal adherence within a prescriber’s patient pool is associated with the extent of age and/or sex concordance</p><p><br></p><p>[I;M NOT SURE IF THIS IS BETTER… JUST EXPERIMENTING WITH DIFFERENT WAYS OF SAYING IT…. PLEASE FEEL FREE TO IGNORE.I FIND THIS SO DIFFICULT TO WRITE.</p><p><a href=\"#_msoanchor_3\" target=\"_blank\">[BD3]</a>What about…</p><p>t///</p>","children":[]},{"idx":"94ae83c2-32f8-4ac3-a469-995d2b610bcc","name":"Obj3 concord to adh individual level","custparents":[{"idx":"48eb234c-14e3-44fb-a544-0a639d7918ce"}],"NodeDescription":"<p>///t</p><p><u>Objective 3: To determine if age/sex concordance with a prescriber increases the probability of achieving optimal adherence for individual patients.</u></p><p>Hypothesis: at individual patient level, age and /or sex concordant between a patient and a prescriber is associated with an increased prevalence of optimal medication adherence.</p><p>t///</p>"}],"NodeDescription":"<p><br></p><p><br></p>"},{"idx":"ec91e1fa-13e5-4cd2-b29f-97e249450864","name":"Study design","custparents":[{"idx":"210a42cb-6db1-4b37-9796-16d79dc503c1"}],"NodeDescription":"<p><br></p>","children":[{"idx":"ad64b271-0d34-4604-b086-d9ae4a19971e","name":"study design and population","custparents":[{"idx":"ec91e1fa-13e5-4cd2-b29f-97e249450864"}],"NodeDescription":"<p>///t</p><p><br></p><p><strong>Study design and population</strong></p><p>A retrospective cohort study was performed including individuals who initiated a new statin medication treatment between January 1, 2012 and December 31, 2017, and general practitioner (GP) physicians who prescribed for these individuals within a 365- day follow-up period on and after the initiation of statin.<a href=\"#_msocom_1\" target=\"_blank\">[EC1]</a><a href=\"#_msoanchor_1\" target=\"_blank\">[EC1]</a>As written here it sounds like you identified a cohort of GPs first, but based on the inclusion criteria section below, it seems like you identified the patients first and then found the physician cohort. Likely not a big deal, but might want to be consistent with how things are described to help the readers follow. </p><p><span style=\"background-color: yellow;\">[SY] Changed</span></p><p>&nbsp;&nbsp;&nbsp;t///</p>"},{"idx":"3c5bacb7-84ed-4e10-a85d-507cb8830421","name":"Source of data","custparents":[{"idx":"210a42cb-6db1-4b37-9796-16d79dc503c1"},{"idx":"ec91e1fa-13e5-4cd2-b29f-97e249450864"}],"NodeDescription":"<p>///t</p><h3>Sources of data</h3><p>Data were extracted from health administrative <a href=\"#_msocom_1\" target=\"_blank\">[g1]</a>databases in the province of Saskatchewan, Canada. These databases include a personal registry file for the provincial health plan<a href=\"#_msocom_2\" target=\"_blank\">[g2]</a>, a physician claims file, a physician registry file, a hospital discharge abstract database, and a prescription drug claims file. Descriptions of these databases, and variables used in this study can be found in Appendix 1<a href=\"#_msocom_3\" target=\"_blank\">[SY3]</a>.<sup>(23)</sup></p><p>“health administrative…” or “administrative health…”</p><p><span style=\"background-color: yellow;\">[SY]Changed</span></p><p>Suggest “ a person registry file for the provincial health plan, …”</p><p><span style=\"background-color: yellow;\">[SY] Changed</span></p><p><a href=\"#_msoanchor_3\" target=\"_blank\">[SY3]</a>Like in project 1, remove the appendix 1</p><p>And put the descriptions back into the text</p><p>t///</p>"},{"idx":"f86e7ab8-10b1-468b-a5d0-c01dcc90fc70","name":"Patient and physician inclusion criteria","custparents":[{"idx":"ec91e1fa-13e5-4cd2-b29f-97e249450864"}],"NodeDescription":"<p>///t</p><h3>Patient and physician inclusion criteria</h3><p>Individuals included in this study were new statin users who were identified by the following criteria: 1) received <a href=\"#_msocom_1\" target=\"_blank\">[g1]</a>a statin medication (DINs listed in Appendix 2) within the inclusion period; 2) did not receive statin medications within a washout-period of 1,825 days prior to the index date (i.e., the date of receiving the first dispensation of a statin medication within the inclusion period).</p><p>Several exclusion criteria were applied before assembling the final cohort, including: 1) missing age or sex information in the personal registration file; 2) less than 18 years old on the index date; 3) not continuously registered for healthcare service within the washout period, or a follow-up period of 365 days after and including the index date; 4) deceased, or termination of benefits during the follow-up period; 5) admitted to a long term care facility within the washout or follow-up period; 6) unable to obtain sufficient data for analysis (e.g., hospitalized in an out-of-province acute care facility during follow-up); 7) pregnant <a href=\"#_msocom_2\" target=\"_blank\">[EC2]</a>within <a href=\"#_msocom_3\" target=\"_blank\">[LL3]</a>365 days prior to the index date, or within the follow-up period (Appendix 9); 8) not receiving statin medications from any general practitioners (GPs, see Appendix 7) within the follow-up period.</p><p>A single prescriber (i.e., statin prescriber) was identified for each individual in the cohort using the following criteria: a) was the most frequently identified prescriber for an individual’s statin dispensations during the follow-up period; and b) was identified as a GP in the physician registration file<a href=\"#_msocom_4\" target=\"_blank\">[LL4]</a>. Prescribers were excluded if they had missing data on age, or sex, or were not connected to at least six individuals during the study<a href=\"#_msocom_5\" target=\"_blank\">[EC5]</a><a href=\"#_msocom_6\" target=\"_blank\">[g6]</a>. <a href=\"#_msocom_7\" target=\"_blank\">[LL7]</a></p><p>Keeping your tenses consistent… you are describing things that happened in the past.</p><p><span style=\"background-color: yellow;\">[SY] Changed</span></p><p><a href=\"#_msoanchor_2\" target=\"_blank\">[EC2]</a>Like project 1, explain how this was determined.</p><p><span style=\"background-color: yellow;\">[SY] Changed</span></p><p><a href=\"#_msoanchor_3\" target=\"_blank\">[LL3]</a>You call this a “washout period” above. Be sure to be consistent in your language. </p><p><span style=\"background-color: yellow;\">[SY] delete the run-in period. </span></p><p><span style=\"background-color: yellow;\">The run-in period is for determination of baseline characteristics. </span></p><p><span style=\"background-color: yellow;\">Here the 365 period prior to index is to exclude pregnant patients. It is kind of wash-out, but the previously defined 5-year washout period is not applicable (5years would be too long to exclude pregnant women). </span></p><p><span style=\"background-color: yellow;\">I do not want to create a second washout period, which would be confusing. So I simply deleted the ‘run-in period’. </span></p><p><br></p><p><a href=\"#_msoanchor_4\" target=\"_blank\">[LL4]</a>So, if an individual had a statin prescribed by a specialist, that specialist and his/her patients would also be excluded? Right? This needs to be clarified. </p><p><span style=\"background-color: yellow;\">[SY] changed, adding into the exclusion criteria</span></p><p><a href=\"#_msoanchor_5\" target=\"_blank\">[EC5]</a>Should have a paragraph describing the adherence measure up here since it’s the same for both objectives. Then you can discuss the time period adherence was measured over, which is missing in your discussion of adherence below. </p><p><span style=\"background-color: yellow;\">[SY] The definition of adherence moved here</span></p><p>agreed</p><p><a href=\"#_msoanchor_7\" target=\"_blank\">[LL7]</a>Doesn’t this also mean that you would exclude the individual patients if their prescriber was excluded? This must be addressed in the exclusion criteria above.</p><p><span style=\"background-color: yellow;\">[SY] added into the exclusion criteria</span></p><p>t///</p>"}]},{"idx":"MY7643458a-d083-47ce-8639-3e17a861d423","name":"Definition of adherence","custparents":[{"idx":"210a42cb-6db1-4b37-9796-16d79dc503c1"}]},{"idx":"MYe1d0d18c-6452-4245-948d-6dbb4e142396","name":"objective 1 random effects","custparents":[{"idx":"210a42cb-6db1-4b37-9796-16d79dc503c1"},{"idx":"210a42cb-6db1-4b37-9796-16d79dc503c1"}]},{"idx":"MY4ec98db0-4922-4bc6-8664-efd878da2864","name":"Objective 2 Physician characters","custparents":[{"idx":"210a42cb-6db1-4b37-9796-16d79dc503c1"},{"idx":"210a42cb-6db1-4b37-9796-16d79dc503c1"}]},{"idx":"MY152a2bd7-98f1-4092-8459-31128c8af760","name":"objs for project 2","custparents":[{"idx":"210a42cb-6db1-4b37-9796-16d79dc503c1"},{"idx":"210a42cb-6db1-4b37-9796-16d79dc503c1"},{"idx":"210a42cb-6db1-4b37-9796-16d79dc503c1"}],"children":[],"_substeps":{"idx":"MY3889e29a-ac13-44a5-b2a4-702e5f601350","name":"substeps","custparents":[{"idx":"MY152a2bd7-98f1-4092-8459-31128c8af760"}],"children":[{"idx":"d06f2ec7-14af-4821-a59f-e1f302586c97","name":"Obj 1 describing % adh % concordance","custparents":[{"idx":"MY3889e29a-ac13-44a5-b2a4-702e5f601350"}],"children":[{"idx":"bfee21cd-45a8-4dca-a3ac-f50b168e4971","name":"Adherence to statin medication","custparents":[{"idx":"d06f2ec7-14af-4821-a59f-e1f302586c97"}],"NodeDescription":"<p>///t</p><h3>Prevalence of optimal adherence linked to specific prescribers</h3><p><a href=\"#_msocom_1\" target=\"_blank\">[g1]</a>Statin adherence was calculated for each individual and was then used to calculate the prescriber-specific prevalence of optimal statin adherence. We measured individual adherence to statin medications using the proportion of days <a href=\"#_msocom_2\" target=\"_blank\">[LL2]</a>covered (PDC<a href=\"#_msocom_3\" target=\"_blank\">[BD3]</a>).<sup>(24)</sup> We included all dispensations of statin within the follow-up period (i.e., 365 days after and including the index date). Days supply was estimated for each dispensation using the number of pills dispensed<a href=\"#_msocom_4\" target=\"_blank\">[EC4]</a><a href=\"#_msocom_5\" target=\"_blank\">[5]</a><a href=\"#_msocom_6\" target=\"_blank\">[g6]</a>, assuming dosing of one pill per day. Overlapping supply days between refills were accumulated. Switching between different classes of statin medications was allowed. Hypothetically, if an individual received 30 pills of a statin medication on June 1, 2015, and received the following 30 pills of another class of statin medication on June 15, 2015, the individual was considered having 60 days supply (regardless of statin classes) between June 1, 2015, and July 30, 2015. PDC was calculated by the following formula:<a href=\"#_msocom_7\" target=\"_blank\">[BD7]</a></p><p>PDC = <a href=\"#_msocom_8\" target=\"_blank\">[g8]</a></p><p>Where number of days covered by the study medications = number of days supply truncated at the end of the follow-up period; Number of eligible days in the follow-up period = the 365 days after and including the index date but excluding days staying in a hospital for acute care. Optimal adherence was defined as PDC&gt;= 80%.<sup>(25)</sup> Details of the PDC method have been described in the literature<a href=\"#_msocom_9\" target=\"_blank\">[EC9]</a>,<sup>(24, 25)</sup></p><p><strong>The prescriber-specific prevalence of optimal adherence was calculated by summing, within each prescriber, the number of individuals with PDC&gt;=80% and dividing by the total number of individual patients for that prescriber. We then created a </strong>dichotomous variable, for use in our regression modeling, to differentiate prescribers with “higher” vs “lower” prevalence of individual patients with optimal adherence, based on whether they were above or below the median level of provider-specific optimal adherence in the study<a href=\"#_msocom_10\" target=\"_blank\">[BD10]</a>.<a href=\"#_msocom_11\" target=\"_blank\">[g11]</a></p><p><strong>A bit awkward - perhaps try “Statin adherence was calculated for each new statin user [or patient/subject] and this was then usedto calculate the prescriber-specific prevalence of optimal statin adherence.”</strong></p><p><strong>Then you could start the next sentence: “Individual patients’ adherence….”</strong></p><p><span style=\"background-color: yellow;\">[SY] Changed</span></p><p><a href=\"#_msoanchor_2\" target=\"_blank\">[LL2]</a>The calculation is percentage of days covered, not proportion</p><p><span style=\"background-color: olive;\">[SY] to be discussed</span></p><p><a href=\"#_msoanchor_3\" target=\"_blank\">[BD3]</a>All this could go up in the section above..</p><p><a href=\"#_msoanchor_4\" target=\"_blank\">[EC4]</a>Similar comment to project 1. Did you use the quantity or the actual days supply variable? If you used the days supply variable, then why the need to estimate it based on dosing…would you not just use what was reported as the days supply? </p><p><span style=\"background-color: yellow;\">[SY] wording changed. The days supply was calculated from # of tablets per dispensation, as there is no days supply variable in the database.</span></p><p><strong>Similar comment to project 1. Did you use the quantity or the actual days supply variable? If you used the days supply variable, then why the need to estimate it based on dosing…would you not just use what was reported as the days supply? </strong></p><p><span style=\"background-color: yellow;\">[SY] Changed</span></p><p><strong>This is a ‘technical term’ of the database - which essentially means “number of pills”.For greater clarity here for the reader who may not be entirely familiar with the drug database - you could just say “using the number of pills dispensed…” here.</strong></p><p><span style=\"background-color: yellow;\">[SY] Changed</span></p><p><a href=\"#_msoanchor_7\" target=\"_blank\">[BD7]</a>Do you think this explanation is necessary?Did someone ask you to provide it?I am thinking it is not needed.</p><p>Since you talk about PDC as a percentage, you need to include multiplication of the right hand side of the equation by 100.</p><p><span style=\"background-color: yellow;\">[SY ]Changed</span></p><p><a href=\"#_msoanchor_9\" target=\"_blank\">[EC9]</a>See suggestions I provided for Project 1 for this part (how hospitalizations were identified, etc…)</p><p><span style=\"background-color: yellow;\">[SY ]Changed</span></p><p><a href=\"#_msoanchor_10\" target=\"_blank\">[BD10]</a>THIS COULD ALSO GO IN THE DESCRIPTION OF OBJECTIVE 1 IF YOU THINK THAT WOULD WORK.</p><p>This paragraph is not entirely clear and includes several ideas.Note: I put options for wording in [square brackets]. This example also shows the benefit of switching to “subject” terminology.</p><p><br></p><p>Suggest “The prescriber-specific prevalence [or proportion] of optimal adherence was calculated by summing, within each prescriber, the number of [patients/subjects] with PDC&gt;=80% and dividing by the total number of [patients/subjects] for that prescriber.We then created a dichotomous variable, for use in our regression modeling, to differentiate providers with “higher” vs “lower” prevalence of patients [subjects] with optimal adherence, based on whether they were above or below the median level of provider-specific optimal adherence in the study.</p><p><span style=\"background-color: yellow;\">[SY ]Changed</span></p><p><br></p><p><br></p><p>t///</p>"},{"idx":"e965e274-96c8-49f9-9dd3-2ea6d257843c","name":"age and sex concordance","custparents":[{"idx":"d06f2ec7-14af-4821-a59f-e1f302586c97"}],"NodeDescription":"<p>///t</p><h3>Determining age/sex concordance between individuals and their statin prescriber</h3><p>For each individual, the GP prescriber’s age was determined on the index date (i.e., date of first statin dispensation). Individuals<a href=\"#_msocom_1\" target=\"_blank\">[g1]</a> were categorized as age concordant if their age at the index date fell within 5 years above or below the prescriber’s age. The proportion of age concordant individuals was calculated for each statin prescriber (using the number of age-concordant individuals <a href=\"#_msocom_2\" target=\"_blank\">[2]</a>divided by the total number of individuals for that prescriber). Sex concordance was also determined based on an exact match between the individual and the statin prescriber. The proportion of sex concordant individuals was calculated for each statin prescriber using the same method as in calculation of proportion of age concordant individuals.<a href=\"#_msocom_3\" target=\"_blank\">[3]</a></p><p>I do agree with Charity.I think if you early on define ‘subjects’s as patients who are new statin users then you can avoid a lot of awkward language later on… bc you can just say “subjects” and the reader will know that you mean patients newly prescribed statins.</p><p><br></p><p>You don’t need to keep using this term since you’ve described your patient population already.</p><p><span style=\"background-color: yellow;\">[SY] changed</span></p><p>You don’t need to keep using this term since you’ve described your patient population already.</p><p><span style=\"background-color: yellow;\">[SY] changed</span></p><p>t///</p>"},{"idx":"38d48c13-6581-4b0e-9f41-a6cfeb54de04","name":"Description statistics","custparents":[{"idx":"d06f2ec7-14af-4821-a59f-e1f302586c97"}],"NodeDescription":"<p>///t</p><p>[_Q] what discriptions</p><p><br></p><p>t///</p><p>[to do]</p>"}]},{"idx":"7de5aa12-ec1a-415c-9968-ca9a7d456f50","name":"Obj 2 doc level % concord to % adh","custparents":[{"idx":"MY3889e29a-ac13-44a5-b2a4-702e5f601350"}],"NodeDescription":"<p>///t<p></p><strong>Objective 1: To examine the extent to which certain GP characteristics were associated with having a high proportion of adherent statin users.</strong><p></p>&nbsp;&nbsp;&nbsp;&nbsp;t///</p>","children":[{"idx":"5240e881-cdfc-4077-bf1e-73b44dbd7edd","name":"Statistical analysis (logistic regression)","custparents":[{"idx":"7de5aa12-ec1a-415c-9968-ca9a7d456f50"}],"NodeDescription":"<p>///t</p><p>t///</p>","children":[]}]},{"idx":"a261e92e-d040-41d5-85c7-c38533636c64","name":"Obj 3 individual level concord to adh","custparents":[{"idx":"MY3889e29a-ac13-44a5-b2a4-702e5f601350"}],"NodeDescription":"<p>///t</p><p>Objective 2: To investigate the extent to which age or sex concordance between a GP and a patient is associated with the patient's adherence to statin medications</p><p><br></p><ol><li data-list=\"ordered\"><span class=\"ql-ui\" contenteditable=\"false\"></span>Age, sex, service year, fee for service time,etc</li><li data-list=\"ordered\"><span class=\"ql-ui\" contenteditable=\"false\"></span>Logistic regression model</li></ol><p><br></p><p>t///</p>","children":[{"idx":"98faf3c4-9013-4d87-8af2-354d3a806efa","name":"Statistical analysis","custparents":[{"idx":"a261e92e-d040-41d5-85c7-c38533636c64"}],"NodeDescription":"<p>///t</p><p>Logistic regression models were built to test the effect of age and sex concordance on the probability of medication adherence for individual patients. The primary independent variables were the age, and sex concordance measures <a href=\"#_msocom_1\" target=\"_blank\">[g1]</a>of each individual. The dependent variable was the occurrence of optimal medication adherence (i.e., yes or no) of individuals after the one-year follow-up period. First, two univariate models were tested respectively, one using age concordance as the independent variable, the other using sex concordance<a href=\"#_msocom_2\" target=\"_blank\">[LL2]</a> as the independent variable. Odds ratio of age concordance, and sex concordance were obtained from the univariate models. </p><p>Next<a href=\"#_msocom_3\" target=\"_blank\">[g3]</a>, a multivariable model was built to test the effect of age and sex concordance adjusted by prescriber-related and patient-related covariates. The generalized estimating equations (GEE) method was used to account for the clustering effect of individual patients within prescribers.<sup>(27)</sup> The identification numbers of the<a href=\"#_msocom_4\" target=\"_blank\">[BD4]</a><a href=\"#_msocom_5\" target=\"_blank\">[BD5]</a>prescribers were used as the repeat term in the GEE models.<a href=\"#_msocom_6\" target=\"_blank\">[g6]</a> The prescriber-related covariates (Appendix 3) included prescribers’ experience (i.e., age, years since graduation, country of graduation), physician salary model (i.e., fee-for-service or non-fee-for-service), and status of comprehensive continuity of care (i.e., the connected prescriber as the usual care provider, and providing complete medical examination as well<a href=\"#_msocom_7\" target=\"_blank\">[BD7]</a>). The literature suggests a five-dimension framework of factors that are potentially associated with medication adherence: patient-related, socioeconomic-related, disease-related, treatment related, and healthcare system-related factors.<sup>(1)</sup> Based on this framework, patient-related covariates (see Appendix 8) were included in the adjusted model. Multicollinearity among the covariates was examined by the variance inflation factor (VIF) obtained from a regression model<a href=\"#_msocom_8\" target=\"_blank\">[LL8]</a>. For covariates with a VIF greater than 2.5, a decision is made to keep the covariate that was more relevant to the analysis<a href=\"#_msocom_9\" target=\"_blank\">[BD9]</a>, using the same principles as in analysis for objective one. Two-way interactions between the primary independent <a href=\"#_msocom_10\" target=\"_blank\">[LL10]</a>variable and the covariates were examined. Interactions with a p value &lt; 0.05 were retained in the model. GEE models using different types of working covariance matrix <a href=\"#_msocom_11\" target=\"_blank\">[LL11]</a>were compared and the one with the smallest quasi-Akaike's information criterion (QAIC) statistic was selected as the final model. Odds ratio (95% CI) of age concordance and sex concordance were obtained from the robust estimators of the final model.</p><p>A bit confusing… here the language used describes a single independent variable -as a single measure of age/sex concordance - whereas above you described two separate independent variables age concordance and sex concordance.If you still intend to be referring to those two variables (which I think you do) then you need to pluralize “variables” and “measures” in this sentence.</p><p><span style=\"background-color: yellow;\">[SY] Changed</span></p><p><a href=\"#_msoanchor_2\" target=\"_blank\">[LL2]</a>Explain what you mean. You fit one model with age and one model with sex – right? </p><p><span style=\"background-color: yellow;\">[SY] Changed</span></p><p>Inserted a a paragraph break here.</p><p><a href=\"#_msoanchor_4\" target=\"_blank\">[BD4]</a></p><p><a href=\"#_msoanchor_5\" target=\"_blank\">[BD5]</a>I took out “statin” because I don’t’ think we referred to them that way previously..I think they are just “prescribers”…right?</p><p>You had this stuff about GEE at the end like an “add on” but in fact you would have done GEE models from the start - so I think it best incorporated here.The rest of the paragraph about GEE I put at the bottom of this para.</p><p><span style=\"background-color: yellow;\">[SY] Yep, thanks</span></p><p><a href=\"#_msoanchor_7\" target=\"_blank\">[BD7]</a>It would be nice if our first paper was published before we submit this so we could cite it here.Otherwise, we may have to clarify this description.</p><p><a href=\"#_msoanchor_8\" target=\"_blank\">[LL8]</a>Same comment as above. </p><p><span style=\"background-color: yellow;\">[SY] changed</span></p><p><a href=\"#_msoanchor_9\" target=\"_blank\">[BD9]</a>To be made more specific</p><p><a href=\"#_msoanchor_10\" target=\"_blank\">[LL10]</a>Not sue what this phrase means. </p><p><span style=\"background-color: yellow;\">[SY] changed, also made change in the previous paragraph. “The primary independent variables were the age, and sex concordance measuresof each individual”</span></p><p><a href=\"#_msoanchor_11\" target=\"_blank\">[LL11]</a>Not clear what you mean. Explain</p><p><span style=\"background-color: yellow;\">[SY] changed to ‘working covariatnce matrix”</span></p><p>t///</p>","children":[{"idx":"54e7d4a9-6c98-4c8b-b313-fa0ece6fdfc4","name":"univariate","custparents":[{"idx":"98faf3c4-9013-4d87-8af2-354d3a806efa"}],"NodeDescription":"<p>///t</p><p>Logistic regression models were built to test the effect of age and sex concordance on the probability of medication adherence for individual patients. The primary independent variables were the age, and sex concordance measures <a href=\"#_msocom_1\" target=\"_blank\">[g1]</a>of each individual. The dependent variable was the occurrence of optimal medication adherence (i.e., yes or no) of individuals after the one-year follow-up period. First, two univariate models were tested respectively, one using age concordance as the independent variable, the other using sex concordance<a href=\"#_msocom_2\" target=\"_blank\">[LL2]</a> as the independent variable. Odds ratio of age concordance, and sex concordance were obtained from the univariate models. </p><p>A bit confusing… here the language used describes a single independent variable -as a single measure of age/sex concordance - whereas above you described two separate independent variables age concordance and sex concordance.If you still intend to be referring to those two variables (which I think you do) then you need to pluralize “variables” and “measures” in this sentence.</p><p><span style=\"background-color: yellow;\">[SY] Changed</span></p><p><a href=\"#_msoanchor_2\" target=\"_blank\">[LL2]</a>Explain what you mean. You fit one model with age and one model with sex – right? </p><p><span style=\"background-color: yellow;\">[SY] Changed</span></p><p>t///</p>"},{"idx":"e469cbc1-19df-44cb-8f8c-fd3ae2c8b054","name":"Multivariate","custparents":[{"idx":"98faf3c4-9013-4d87-8af2-354d3a806efa"}],"NodeDescription":"<p>///t</p><p>Next<a href=\"#_msocom_1\" target=\"_blank\">[g1]</a>, a multivariable model was built to test the effect of age and sex concordance adjusted by prescriber-related and patient-related covariates. The generalized estimating equations (GEE) method was used to account for the clustering effect of individual patients within prescribers.<sup>(27)</sup> The identification numbers of the<a href=\"#_msocom_2\" target=\"_blank\">[BD2]</a><a href=\"#_msocom_3\" target=\"_blank\">[BD3]</a>prescribers were used as the repeat term in the GEE models.<a href=\"#_msocom_4\" target=\"_blank\">[g4]</a> The prescriber-related covariates (Appendix 3) included prescribers’ experience (i.e., age, years since graduation, country of graduation), physician salary model (i.e., fee-for-service or non-fee-for-service), and status of comprehensive continuity of care (i.e., the connected prescriber as the usual care provider, and providing complete medical examination as well<a href=\"#_msocom_5\" target=\"_blank\">[BD5]</a>). The literature suggests a five-dimension framework of factors that are potentially associated with medication adherence: patient-related, socioeconomic-related, disease-related, treatment related, and healthcare system-related factors.<sup>(1)</sup> Based on this framework, patient-related covariates (see Appendix 8) were included in the adjusted model. Multicollinearity among the covariates was examined by the variance inflation factor (VIF) obtained from a regression model<a href=\"#_msocom_6\" target=\"_blank\">[LL6]</a>. For covariates with a VIF greater than 2.5, a decision is made to keep the covariate that was more relevant to the analysis<a href=\"#_msocom_7\" target=\"_blank\">[BD7]</a>, using the same principles as in analysis for objective one. Two-way interactions between the primary independent <a href=\"#_msocom_8\" target=\"_blank\">[LL8]</a>variable and the covariates were examined. Interactions with a p value &lt; 0.05 were retained in the model. GEE models using different types of working covariance matrix <a href=\"#_msocom_9\" target=\"_blank\">[LL9]</a>were compared and the one with the smallest quasi-Akaike's information criterion (QAIC) statistic was selected as the final model. Odds ratio (95% CI) of age concordance and sex concordance were obtained from the robust estimators of the final model.</p><p>Inserted a a paragraph break here.</p><p><a href=\"#_msoanchor_2\" target=\"_blank\">[BD2]</a></p><p><a href=\"#_msoanchor_3\" target=\"_blank\">[BD3]</a>I took out “statin” because I don’t’ think we referred to them that way previously..I think they are just “prescribers”…right?</p><p>You had this stuff about GEE at the end like an “add on” but in fact you would have done GEE models from the start - so I think it best incorporated here.The rest of the paragraph about GEE I put at the bottom of this para.</p><p><span style=\"background-color: yellow;\">[SY] Yep, thanks</span></p><p><a href=\"#_msoanchor_5\" target=\"_blank\">[BD5]</a>It would be nice if our first paper was published before we submit this so we could cite it here.Otherwise, we may have to clarify this description.</p><p><a href=\"#_msoanchor_6\" target=\"_blank\">[LL6]</a>Same comment as above. </p><p><span style=\"background-color: yellow;\">[SY] changed</span></p><p><a href=\"#_msoanchor_7\" target=\"_blank\">[BD7]</a>To be made more specific</p><p><a href=\"#_msoanchor_8\" target=\"_blank\">[LL8]</a>Not sue what this phrase means. </p><p><span style=\"background-color: yellow;\">[SY] changed, also made change in the previous paragraph. “The primary independent variables were the age, and sex concordance measuresof each individual”</span></p><p><a href=\"#_msoanchor_9\" target=\"_blank\">[LL9]</a>Not clear what you mean. Explain</p><p><span style=\"background-color: yellow;\">[SY] changed to ‘working covariatnce matrix”</span></p><p>t///</p>"}]},{"idx":"4b240c50-c506-4006-b9a3-b5828ecaf4ad","name":"sensitivity analyses","custparents":[{"idx":"a261e92e-d040-41d5-85c7-c38533636c64"}],"children":[{"idx":"98b4a9bd-8bc4-4e62-a6ca-17587bdb5597","name":"10 years concordance","custparents":[{"idx":"4b240c50-c506-4006-b9a3-b5828ecaf4ad"},{"idx":"4b240c50-c506-4006-b9a3-b5828ecaf4ad"}],"NodeDescription":"<p>///t</p><p>The analyses were repeated for alternative measures of concordance. First, age concordance was measured by a broader range of years (i.e., if the age difference between an individual and his/her statin prescriber was within ± 10 years, age concordance =1; otherwise age concordance =0).</p><p>t///</p>"},{"idx":"f0146d0e-f0d9-4324-af43-aa1e08257ea7","name":"4 levels of concordance instead of 2","custparents":[{"idx":"4b240c50-c506-4006-b9a3-b5828ecaf4ad"},{"idx":"4b240c50-c506-4006-b9a3-b5828ecaf4ad"}],"NodeDescription":"<p>///t</p><p>Second, age concordance <a href=\"#_msocom_1\" target=\"_blank\">[SY1]</a>were measured by four subgroups<a href=\"#_msocom_2\" target=\"_blank\">[g2]</a>: 1) the statin prescriber is younger than the new statin user by more than five years; 2) the statin prescriber is younger by up to five years; 3) the statin prescriber is of the same age, or older by up to five years; and 4) the statin prescriber is older by more than five years. Sex concordance <a href=\"#_msocom_3\" target=\"_blank\">[SY3]</a>was also measured by four groups: 1) the statin prescriber and the new statin user were both females; 2) the statin prescriber and the new statin user were both males; 3) the statin prescriber was a female, and the new statin user was a male; 4) the statin prescriber was a male, and the new statin user was a female<a href=\"#_msocom_4\" target=\"_blank\">[EC4]</a>. <a href=\"#_msoanchor_1\" target=\"_blank\">[SY1]</a></p><p><span style=\"background-color: yellow;\">The original word ‘age/sex’ concordance was misleading. </span></p><p><span style=\"background-color: yellow;\">Age concordance is measured separately from sex concordance.</span></p><p><span style=\"background-color: yellow;\">This part is to define 4 groups on age concordance</span></p><p>I think you mean just “age concordance” here not age/sex.</p><p><span style=\"background-color: yellow;\">[SY]Changed</span></p><p><a href=\"#_msoanchor_3\" target=\"_blank\">[SY3]</a><span style=\"background-color: yellow;\">This part is to define sex concordance in 4 groups</span></p><p><a href=\"#_msoanchor_4\" target=\"_blank\">[EC4]</a>Maybe you’re measuring this already and I just missed it, but what about if the age AND sex are concordant, the sex is concordant but not age, the age is concordant but not sex, neither are concordant? </p><p><span style=\"background-color: yellow;\">[SY]Age concordance and sex concordance are measured and analyzed separately.</span></p><p><br></p><p>t///</p>"}]}]}]}}]}]}],"NodeDescription":"<p>///t</p><p>based on</p><p>f:\\personal\\Dropbox\\Project\\The PhD Thesis Project\\Proposal and thesis\\Submissions to committee\\Proposals\\PhD2 The impact of age and sex concordance on medication adherence_20200415.docx</p><p><br></p><p>t///</p>"}],"NodeDescription":"<p><br></p><p>[_W][to do]</p><p>The project 2 will use the statin cohort prepared in project 1.</p><p>The sas egp is</p><p>F:\\Personal\\Dropbox\\Project\\The PhD Thesis Project\\Proposal and thesis\\Project2\\SAS code\\PhD_GPCharactStatin_20200228.egp</p><p>The patient cohort is in VXM_FS, the first program for project 2 is ZXA.</p><p><br></p><p>Several reports by ZXA can be found at:</p><p>F:\\Personal\\Dropbox\\Project\\The PhD Thesis Project\\Proposal and thesis\\Project2\\Reports\\ReportZXA.xlsx</p><p><br></p><p><br></p><ol><li data-list=\"ordered\"><span class=\"ql-ui\" contenteditable=\"false\"></span>A 2-year period should bring enough power for the analysis. The following chart shows within a 2-year period of time, around 20,000 patients can be identified in the analyses</li></ol><table><tbody><tr><td data-row=\"1\">EntryYear</td><td data-row=\"1\"># Patients</td></tr><tr><td data-row=\"3\" class=\"ql-align-right\">2012</td><td data-row=\"3\" class=\"ql-align-right\">9253</td></tr><tr><td data-row=\"4\" class=\"ql-align-right\">2013</td><td data-row=\"4\" class=\"ql-align-right\">8407</td></tr><tr><td data-row=\"5\" class=\"ql-align-right\">2014</td><td data-row=\"5\" class=\"ql-align-right\">8841</td></tr><tr><td data-row=\"6\" class=\"ql-align-right\">2015</td><td data-row=\"6\" class=\"ql-align-right\">9062</td></tr><tr><td data-row=\"7\" class=\"ql-align-right\">2016</td><td data-row=\"7\" class=\"ql-align-right\">9357</td></tr><tr><td data-row=\"8\" class=\"ql-align-right\">2017</td><td data-row=\"8\" class=\"ql-align-right\">9575</td></tr></tbody></table><ol><li data-list=\"ordered\"><span class=\"ql-ui\" contenteditable=\"false\"></span>For each USP, the number of statin patients were also stable. The following chart shows that for &gt;70%, the deviation is &lt; 25% of the mean number of statin patients over the different time periods</li></ol><p><img src=\"data:image/png;base64,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\"></p><p>3a. The percentage of adherent patients is also stable over different periods. The following shows that within different inclusion period, the mean/median # of adherent patients did not change much (slightly increased though)</p><table><tbody><tr><td data-row=\"1\">InclusionPeriods</td><td data-row=\"1\">mean</td><td data-row=\"1\">median</td></tr><tr><td data-row=\"2\" class=\"ql-align-right\">1213</td><td data-row=\"2\" class=\"ql-align-right\">52.4%</td><td data-row=\"2\" class=\"ql-align-right\">53.8%</td></tr><tr><td data-row=\"3\" class=\"ql-align-right\">1314</td><td data-row=\"3\" class=\"ql-align-right\">52.2%</td><td data-row=\"3\" class=\"ql-align-right\">52.2%</td></tr><tr><td data-row=\"4\" class=\"ql-align-right\">1415</td><td data-row=\"4\" class=\"ql-align-right\">53.5%</td><td data-row=\"4\" class=\"ql-align-right\">53.3%</td></tr><tr><td data-row=\"5\" class=\"ql-align-right\">1516</td><td data-row=\"5\" class=\"ql-align-right\">53.7%</td><td data-row=\"5\" class=\"ql-align-right\">55.3%</td></tr><tr><td data-row=\"6\" class=\"ql-align-right\">1617</td><td data-row=\"6\" class=\"ql-align-right\">54.9%</td><td data-row=\"6\" class=\"ql-align-right\">55.1%</td></tr></tbody></table><p>3b. The percentage of adherent patients per USP was also stable. Each USP was categorized into 2 categories, each for High/low % of adherent patients within different 2-year periods (e.g., 1213, 1516,etc.) 291 USPs consistently having no 2-year periods that the number of adherent patients were above median. 244 USPs consistently having all periods that the number of adherent patients were above median. &gt;70% USPs consistently belonged to the H/L group for majority (80%) of the periods.</p><p><img src=\"data:image/png;base64,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\"></p>"},{"idx":"MYd88ed708-a53b-4416-a8cf-0c342dcbf34a","name":"About glimmix","custparents":[{"idx":"f27298ed-15be-4fba-b1f8-f10b2f3f6592"},{"idx":"f27298ed-15be-4fba-b1f8-f10b2f3f6592"}],"children":[],"_substeps":{"idx":"MYc7b16afd-fe7c-49d7-aec6-82231e44fb18","name":"substeps","custparents":[{"idx":"MYd88ed708-a53b-4416-a8cf-0c342dcbf34a"}],"children":[{"idx":"MYec5ca3c2-f850-4f82-9ab7-12dc7ed4d2bc","name":"About glimmix","custparents":[{"idx":"MYc7b16afd-fe7c-49d7-aec6-82231e44fb18"}],"children":[{"idx":"ad56172f-b770-4148-9143-daa3ce2e14af","name":"glimmix","custparents":[{"idx":"MYe43680cb-d907-4acc-960c-44d7e20b15d8"},{"idx":"MYec5ca3c2-f850-4f82-9ab7-12dc7ed4d2bc"}],"NodeDescription":"<p>///t</p><p><br></p><p>F:\\Personal\\Library\\Learning\\Statistics\\MultiLevel Random mixed effect\\Glimmix Mix EG43.egp</p><p>F:\\Personal\\Dropbox\\Project\\SDP Impact\\Sharpen the saw\\Skovgaard's Lecture and examples\\Glimmix MOR example\\MOR example.egp</p><p>F:\\Personal\\Library\\Learning\\Statistics\\MultiLevel Random mixed effect</p><p><br></p><p>t///</p><p>[to do][_Q]</p>"},{"idx":"e9ddbb14-258e-4dcc-be23-a3e4cac4b4e1","name":"Glimmix","custparents":[{"idx":"MY2da04b60-f5a9-4e63-ae83-f9839aa46823"},{"idx":"MY26483ce1-4a1d-4c16-ab2e-57fa60c10820"},{"idx":"MYec5ca3c2-f850-4f82-9ab7-12dc7ed4d2bc"}],"NodeDescription":"<p>///t</p><p>t///</p><p>[_Q][to do]</p><p>This is a great paper on glimmix</p><p><a href=\"https://www.sas.com/content/dam/SAS/support/en/sas-global-forum-proceedings/2018/2179-2018.pdf\" target=\"_blank\">https://www.sas.com/content/dam/SAS/support/en/sas-global-forum-proceedings/2018/2179-2018.pdf</a></p><p><br></p><p>The Proc glimmix is probmatic</p><ol><li data-list=\"ordered\"><span class=\"ql-ui\" contenteditable=\"false\"></span>it has problems of insufficient memory</li><li data-list=\"ordered\"><span class=\"ql-ui\" contenteditable=\"false\"></span>It has problems of non-convergence</li><li data-list=\"ordered\"><span class=\"ql-ui\" contenteditable=\"false\"></span>it shows weird results that are way different from the results from GEE</li></ol><p>The following might help as it compares Glimmix, R ...</p><p><a href=\"https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-11-77\" target=\"_blank\">https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-11-77</a></p><p><br></p><p><br></p>","children":[{"idx":"0f12057e-16b8-463c-8c1e-d58866f8fd17","name":"Resources on Glimmix Methods","custparents":[{"idx":"e9ddbb14-258e-4dcc-be23-a3e4cac4b4e1"}],"NodeDescription":"<p>///t</p><p>t///</p><p>[_Q][_W][to do]</p><p><br></p><p>Lots of sources in</p><p><a href=\"https://shenzhenyao.wordpress.com/2019/10/07/source-for-mor-icc-median-odds-ratio/\" target=\"_blank\">https://shenzhenyao.wordpress.com/2019/10/07/source-for-mor-icc-median-odds-ratio/</a></p><p>on</p><p>ICC, MOR</p><p>In which:</p><ol><li data-list=\"ordered\"><span class=\"ql-ui\" contenteditable=\"false\"></span>formulas to calculate ICC, MOR: <a href=\"https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-12-28\" target=\"_blank\">https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-12-28</a></li><li data-list=\"ordered\"><span class=\"ql-ui\" contenteditable=\"false\"></span>MOR (page 46-58): <a href=\"http://staff.pubhealth.ku.dk/~jufo/courses/rm/lectures/varcomp2-2x2.pdf\" target=\"_blank\">http://staff.pubhealth.ku.dk/~jufo/courses/rm/lectures/varcomp2-2x2.pdf</a></li><li data-list=\"ordered\"><span class=\"ql-ui\" contenteditable=\"false\"></span>Multiple membership multiple models (patients treated by 2 nurses) <a href=\"https://www.ihrp.uic.edu/files/CrossClassMultiMember-Hedeker2014.pdf\" target=\"_blank\">https://www.ihrp.uic.edu/files/CrossClassMultiMember-Hedeker2014.pdf</a></li></ol><p>Also, a lot of papers listed in the blog, many related to ICC, MOR.</p><p><br></p><p>Other sources:</p><ol><li data-list=\"ordered\"><span class=\"ql-ui\" contenteditable=\"false\"></span>Analyzing multiple membership hierarchical data using PROC GLIMMIX (for project 3) <a href=\"https://www.lexjansen.com/wuss/2017/100_Final_Paper_PDF.pdf\" target=\"_blank\">https://www.lexjansen.com/wuss/2017/100_Final_Paper_PDF.pdf</a></li><li data-list=\"ordered\"><span class=\"ql-ui\" contenteditable=\"false\"></span>ICC :Multilevel Models for Categorical Data Using SAS® PROC GLIMMIX: The Basics <a href=\"https://support.sas.com/resources/papers/proceedings15/3430-2015.pdf\" target=\"_blank\">https://support.sas.com/resources/papers/proceedings15/3430-2015.pdf</a></li><li data-list=\"ordered\"><span class=\"ql-ui\" contenteditable=\"false\"></span>On multiple membership, and cross classified models:An Introduction and Integration of Cross-Classified, Multiple Membership, and Dynamic Group Random-Effects Models. (for project 3) <a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784720/\" target=\"_blank\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784720/</a></li></ol><p><br></p>"}]},{"idx":"MY5fba2bee-dee3-4404-8cda-9c7b0c2e43ab","name":"Cross Class Multi Member Glimmix","custparents":[{"idx":"MYec5ca3c2-f850-4f82-9ab7-12dc7ed4d2bc"}],"NodeDescription":"<p>///t</p><p>F:\\Personal\\Dropbox\\Project\\CrossClassMultiMemberGlimmix</p><p>t///</p>","children":[{"idx":"MY2883410d-3b35-4a9d-800a-d53c896b7587","name":"only cross-class glimmix","custparents":[{"idx":"MY5fba2bee-dee3-4404-8cda-9c7b0c2e43ab"}],"NodeDescription":"<p>///t</p><iframe class=\"ql-video\" frameborder=\"0\" allowfullscreen=\"true\" src=\"https://www.youtube.com/embed/6B8J-NNYEwk?showinfo=0\" data-blot-formatter-unclickable-bound=\"true\"></iframe><p><br></p><p><br></p><p>A simple explanation on cross-classification models using SAS</p><p><strong>With SAS code, and with interpretation of results</strong></p><p><a href=\"https://support.sas.com/resources/papers/proceedings11/348-2011.pdf\" target=\"_blank\">https://support.sas.com/resources/papers/proceedings11/348-2011.pdf</a></p><p><br></p><p><br></p><p>A thesis on cross-classified structure (page 19)</p><p><strong>With SAS code on data generation, and CCREM SAS code</strong></p><p><a href=\"https://etd.ohiolink.edu/!etd.send_file?accession=osu1322538958&amp;disposition=inline\" target=\"_blank\">https://etd.ohiolink.edu/!etd.send_file?accession=osu1322538958&amp;disposition=inline</a></p><p><br></p><p>Kernan</p><p>Tips and Strategies for Mixed Modeling with SAS/STAT® Procedures</p><p><a href=\"https://support.sas.com/resources/papers/proceedings12/332-2012.pdf\" target=\"_blank\">https://support.sas.com/resources/papers/proceedings12/332-2012.pdf</a></p><p>Two-step approach (Proc Hpmixed, then Proc Mixed) in case proc glimmix blows computer resources.</p><p><strong>Same method used in Cafri's example (see the appendix doc)</strong></p><p><br></p><p>t///</p>"},{"idx":"MY8d3ce9b6-8851-4494-97af-17e49d8f4936","name":"only multiple membership glimmix","custparents":[{"idx":"MY5fba2bee-dee3-4404-8cda-9c7b0c2e43ab"}],"NodeDescription":"<p>///t</p><iframe class=\"ql-video\" frameborder=\"0\" allowfullscreen=\"true\" src=\"https://www.youtube.com/embed/kK30GMrnoN0?showinfo=0\" data-blot-formatter-unclickable-bound=\"true\"></iframe><p><br></p><p>t///</p>"},{"idx":"MY13b57b22-d712-4f79-8fe8-b50d31d193a0","name":"Combined","custparents":[{"idx":"MY5fba2bee-dee3-4404-8cda-9c7b0c2e43ab"}],"NodeDescription":"<p>///t</p><iframe class=\"ql-video\" frameborder=\"0\" allowfullscreen=\"true\" src=\"https://www.youtube.com/embed/Uu4GmjzS-qU?showinfo=0\" data-blot-formatter-unclickable-bound=\"true\"></iframe><p><br></p><iframe class=\"ql-video\" frameborder=\"0\" allowfullscreen=\"true\" src=\"https://www.youtube.com/embed/Cvrc50XkJL8?showinfo=0\" data-blot-formatter-unclickable-bound=\"true\"></iframe><p><br></p><p>t///</p>","children":[{"idx":"MY57bab0f4-033c-482c-a884-49604c1f3b20","name":"Application AZZG","custparents":[{"idx":"MY13b57b22-d712-4f79-8fe8-b50d31d193a0"}]}]}]},{"idx":"MYe2c9b6e7-37a9-477d-84f1-29ef5392098b","name":"Median OR (MOR) and ICC","custparents":[{"idx":"MYec5ca3c2-f850-4f82-9ab7-12dc7ed4d2bc"}],"NodeDescription":"<p>///t</p><p><br></p><p><strong>I think I solved it. See Program MCMC in F:\\Personal\\Dropbox\\Project\\CrossClassMultiMemberGlimmix\\SAS code\\CrossOverMultipleMembershipGlimmix.egp</strong></p><p><br></p><p><strong>and this video</strong></p><iframe class=\"ql-video\" frameborder=\"0\" allowfullscreen=\"true\" src=\"https://www.youtube.com/embed/_f4hxNNxypA?showinfo=0\" data-blot-formatter-unclickable-bound=\"true\"></iframe><p><br></p><p><br></p><p><br></p><p>Li, Logistic random effects regression models: a comparison of statistical packages for binary and ordinal outcomes.[<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/21605357\" target=\"_blank\" style=\"background-color: rgb(255, 255, 255); color: rgb(100, 42, 143);\">21605357</a>]</p><p><strong>This one might be great. Ney.. pretty complicated</strong></p><p><br></p><p><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112198/\" target=\"_blank\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112198/</a></p><p>Additional file 2 is with PROC GLIMMX and PROC MCMC code on multiple level model, as well as MLwiN code (check if can find clue for MOR) ! no, there is no magic to obtain the MOR directly from PROC MCMC</p><p><br></p><p><strong>Details about fitting mixed model with PROC MCMC</strong></p><p>Chen<strong>, </strong>Fitting Your Favorite Mixed Models with PROC MCMC</p><p><a href=\"https://support.sas.com/resources/papers/proceedings16/SAS5601-2016.pdf\" target=\"_blank\">https://support.sas.com/resources/papers/proceedings16/SAS5601-2016.pdf</a></p><p><br></p><p><br></p><p>Merlo's paper described the formula of MOR. 95%CL was from MLwiN, but no details, check the references..</p><p><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566165/\" target=\"_blank\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566165/</a></p><p>Formula from the paper above</p><p>ICC = VA / (VA+3.29)</p><p>MOR = EXP((2*VA) ^ (1/2) *0.6745) = exp(0.95 * SqrRoot(VA))</p><p>Example (on page 294, according to table 2, and equation (6)</p><p><br></p><table><tbody><tr><td data-row=\"row-i4se\"><br></td><td data-row=\"row-i4se\">Formula</td><td data-row=\"row-i4se\">Result</td></tr><tr><td data-row=\"row-4aif\">Cluster level variance (VA)</td><td data-row=\"row-4aif\">Given in Table 2</td><td data-row=\"row-4aif\">.275</td></tr><tr><td data-row=\"row-dvh1\">ICC (using latent variable method)</td><td data-row=\"row-dvh1\">ICC = VA/ (VA+3.29)</td><td data-row=\"row-dvh1\">0.077</td></tr><tr><td data-row=\"row-beh5\">MOR</td><td data-row=\"row-beh5\">MOR = EXP((2*VA) ^ (1/2) *0.6745)</td><td data-row=\"row-beh5\">1.65</td></tr><tr><td data-row=\"row-wk1r\">MOR 95%CrI</td><td data-row=\"row-wk1r\">\"Also, using the MCMC method available in MLwiN and other software, we can directly compute a 95% credible interval (CrI) for the MOR using the posterior distribution of the area variance (cluster variance) and compute the MOR for the 2.5th and 97.5th percentiles of the resulting distribution\"</td><td data-row=\"row-wk1r\"><br></td></tr><tr><td data-row=\"row-ak11\">OR of Area level variable(H/L achieve)</td><td data-row=\"row-ak11\">Given in Table 2</td><td data-row=\"row-ak11\">1.95</td></tr><tr><td data-row=\"row-yojx\">Beta</td><td data-row=\"row-yojx\">=ln(OR)</td><td data-row=\"row-yojx\">0.6678</td></tr><tr><td data-row=\"row-26i8\">IOR lower</td><td data-row=\"row-26i8\">Exp(Beta+ (2 * VA) ^ (1/2) * (-1.2816))</td><td data-row=\"row-26i8\">0.75</td></tr><tr><td data-row=\"row-ebp4\">IOR upper</td><td data-row=\"row-ebp4\">Exp(Beta+ (2 * VA) ^ (1/2) * (1.2816))</td><td data-row=\"row-ebp4\">5.05</td></tr></tbody></table><p><br></p><p><br></p><p>[Ref in this paper on MOR?</p><p><span style=\"background-color: rgb(255, 255, 255); color: rgb(0, 0, 0);\">8.Larsen K, Merlo J. Appropriate assessment of neighborhood effects on individual health—integrating random and fixed effects in multilevel logistic regression.Am J Epidemiol200516181–88. [</span><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/15615918\" target=\"_blank\" style=\"background-color: rgb(255, 255, 255); color: rgb(100, 42, 143);\">PubMed</a><span style=\"background-color: rgb(255, 255, 255); color: rgb(0, 0, 0);\">][</span><a href=\"https://scholar.google.com/scholar_lookup?journal=Am+J+Epidemiol&amp;volume=161&amp;publication_year=2005&amp;pages=81-88&amp;pmid=15615918&amp;\" target=\"_blank\" style=\"background-color: rgb(255, 255, 255); color: rgb(100, 42, 143);\">Google Scholar</a><span style=\"background-color: rgb(255, 255, 255); color: rgb(0, 0, 0);\">]</span></p><p>F:\\Personal\\Published Papers\\Papers\\AutoDownload\\Untreated pdf\\15615918 Larsen-2005-logistic regression random effects.pdf</p><p><strong>This paper contains the same formula as in the paper above</strong></p><p><br></p><p><br></p><p><strong>The formula of Median OR was given, but nothing mentioned for the 95%CI</strong></p><p><span style=\"color: rgb(0, 0, 0);\">9.Larsen K, Petersen J H, Budtz‐Jorgensen E.</span><em style=\"color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);\">et al</em><span style=\"color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);\">Interpreting parameters in the logistic regression model with random effects.Biometrics200056909–914. [</span><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/10985236\" target=\"_blank\" style=\"color: rgb(100, 42, 143); background-color: rgb(255, 255, 255);\">PubMed</a><span style=\"color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);\">][</span><a href=\"https://scholar.google.com/scholar_lookup?journal=Biometrics&amp;volume=56&amp;publication_year=2000&amp;pages=909-914&amp;pmid=10985236&amp;\" target=\"_blank\" style=\"color: rgb(100, 42, 143); background-color: rgb(255, 255, 255);\">Google Scholar</a><span style=\"color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);\">]</span></p><p>]</p><p><br></p><p>in the slide there is a formula to calculate MOR, but no 95% CL</p><p>MOR (page 46-58): <a href=\"http://staff.pubhealth.ku.dk/~jufo/courses/rm/lectures/varcomp2-2x2.pdf\" target=\"_blank\">http://staff.pubhealth.ku.dk/~jufo/courses/rm/lectures/varcomp2-2x2.pdf</a></p><p><strong>The same formula as in the table above</strong></p><p><br></p><p>The following EGP file has a data set and sample GLIMMIX Code, named MOR, but no MOR calculation inside</p><p>F:\\Personal\\Dropbox\\Project\\SDP Impact\\Sharpen the saw\\Skovgaard's Lecture and examples\\Glimmix MOR example\\MOR example.egp</p><p>formula also giving in this paper</p><p><a href=\"https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-12-28\" target=\"_blank\">https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-12-28</a></p><p><strong>The same formula as in the table above</strong></p><p><br></p><p>in Browne's manual, many places of median, 2.5% 97.5% percentile, not sure if it is MOR</p><p><a href=\"about:blank\" target=\"_blank\">file:///F:/Personal/Library/Learning/Statistics/MultiLevel%20Random%20mixed%20effect/Browne%202015%20MCMC%20estimation%20in%20MLwiN%20version%202.pdf</a></p><p><br></p><p><br></p><p><br></p><p>Kelvyn Jones mentioned using MCMC by MLwiN, but there was no details</p><p>(page 30)</p><p>F:\\Personal\\Library\\Learning\\Statistics\\SAS\\SAS Bayesian\\SAS bayesian course\\Data\\Vol2Traingmanual2013.docx</p><p>[Ref</p><p>[1] Larsen K, and Merlo J. (2005)Appropriate assessment of neighbourhood effects on individual health: Integrating random and fixed effects in multilevel logistic regression<em>. Am J Epidemio</em>l, 161,81-8;</p><p>Merlo J, Chaix B, Yang M, Lynch J, Rastam L. (2005) A brief conceptual tutorial of multilevel analysis in social epidemiology: linking the statistical concept of clustering to the idea of contextual phenomenon<em>. J Epidemiol Community Health</em> 2005;59(6):443-9.]</p><p><br></p><p><strong>Formula of MOR, as well as R code, nothing mentioned on 95%CI</strong></p><p>Austin</p><p>F:\\Personal\\Published Papers\\Papers\\AutoDownload\\Untreated pdf\\28543517 Austin 2017 intermediate and advanced topics in multilevel logistic regression analysis.pdf</p><p><br></p><p><strong>Useless, not know what the author is talking about</strong></p><p><a href=\"https://pdfs.semanticscholar.org/f481/3bed71884a59dd259deaa78524cf9975b0a7.pdf\" target=\"_blank\">https://pdfs.semanticscholar.org/f481/3bed71884a59dd259deaa78524cf9975b0a7.pdf</a></p><p><br></p><p><strong>Formula of MOR, no 95% CI</strong></p><p>Sanagou, Hospital-level associations with 30-day patient mortality after cardiac surgery: a tutorial on the application and interpretation of marginal and multilevel logistic regressionl</p><p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366874/</p><p><br></p><p>Merlo, An Original Stepwise Multilevel Logistic Regression Analysis of Discriminatory Accuracy: The Case of Neighbourhoods and Health</p><p><strong>Formula of MOR in excel, Data and program files (not sure whether with MOR calculation) in MLwiN format</strong></p><p>https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0153778</p><p>t///</p>","children":[{"idx":"MY87280aa8-7e42-4cb0-bbfe-1c99c2db8c59","name":"MCMC for mixed models","custparents":[{"idx":"MYe2c9b6e7-37a9-477d-84f1-29ef5392098b"}],"NodeDescription":"<p>///t</p><p>t///</p><p>This is to understand the basics of MCMC</p><p><br></p><p><strong>Not a great tutorial. Need a step by step one...</strong></p><p><a href=\"https://support.sas.com/resources/papers/proceedings17/SAS0478-2017.pdf\" target=\"_blank\">https://support.sas.com/resources/papers/proceedings17/SAS0478-2017.pdf</a></p><p><a href=\"https://support.sas.com/resources/papers/proceedings16/SAS5601-2016.pdf\" target=\"_blank\">https://support.sas.com/resources/papers/proceedings16/SAS5601-2016.pdf</a></p><p>The author has a presentation here:</p><p><a href=\"https://www.bayes-pharma.org/wp-content/uploads/2014/10/FangChen_MCMC.pdf\" target=\"_blank\">https://www.bayes-pharma.org/wp-content/uploads/2014/10/FangChen_MCMC.pdf</a></p><p><br></p><p><br></p>","children":[{"idx":"MYceb5aec5-d022-4952-9a6a-5297e347e4ed","name":"Basics about multilevel models","custparents":[{"idx":"MY87280aa8-7e42-4cb0-bbfe-1c99c2db8c59"}],"NodeDescription":"<p>///t</p><p><a href=\"https://stats.idre.ucla.edu/other/mult-pkg/introduction-to-generalized-linear-mixed-models/\" target=\"_blank\">https://stats.idre.ucla.edu/other/mult-pkg/introduction-to-generalized-linear-mixed-models/</a></p><p>t///</p>"}]}]},{"idx":"MY967b43a1-1607-48be-b462-45a322281a5b","name":"check another EGP","custparents":[{"idx":"MYec5ca3c2-f850-4f82-9ab7-12dc7ed4d2bc"}],"NodeDescription":"<p>///t</p><p>check this, which is based on the lecture slides, may help in cross check the calculation for ICC and MOR</p><p>F:\\Personal\\Dropbox\\Project\\SDP Impact\\Sharpen the saw\\Skovgaard's Lecture and examples\\Glimmix MOR example\\MOR example.egp</p><p><br></p><p>[_Q][to do]</p><p>t///</p>"}],"NodeDescription":"<p>///t</p><p>Introduction</p><iframe class=\"ql-video\" frameborder=\"0\" allowfullscreen=\"true\" src=\"https://www.youtube.com/embed/SLDN3m5mMyA?showinfo=0\" data-blot-formatter-unclickable-bound=\"true\"></iframe><p><br></p><p>t///</p>"}]}}],"NodeDescription":"<p>///t</p><iframe class=\"ql-video\" frameborder=\"0\" allowfullscreen=\"true\" src=\"https://www.youtube.com/embed/Uu4GmjzS-qU?showinfo=0\" data-blot-formatter-unclickable-bound=\"true\"></iframe><p><br></p><p><br></p><p>t///</p>"}